GREATER FLEXIBILITY IN MEDICINE SAFETY PROGRAMS DELIVERED BY PHARMACISTS Advocacy leads to Home Medicines Reviews and Residential Medication Management Reviews by telehealth
With
Brooke Shelly FPS, Board Director & PSA Strategic Agreements Lead
Pharmaceutical Society of Australia (PSA)
SEGMENT
Filmed in Sydney | August 2026
Addressing delegates at PSA26, the Pharmaceutical Society of Australia’s (PSA) yearly conference, the Minister for Health and Ageing, the Hon. Mark Butler MP, announced negotiations are progressing on the First Pharmacy Programs Agreement (1PPA), and that from 1 November, follow-up services for Home Medicines Reviews (HMRs) and Residential Medication Management Reviews (RMMRs) programs will be able to be delivered via telehealth.
PSA National President, Professor Mark Naunton MPS, welcomed the announcement, declaring it an important step in modernising pharmacist-delivered care and improving patient access to medication safety programs, particularly for those in rural and remote Australia who may have limited access to healthcare.
Brooke Shelly FPS, PSA Strategic Agreements Lead and Board Director, spoke with Australian Health Journal, stating the announcement was an important step forward for the profession, with the ability for pharmacists to now use telehealth for follow ups aligning medicines safety programs more closely with other sectors of the health system.
“This reform reflects years of hard-fought advocacy from PSA and demonstrates what can be achieved when government and the profession work together with a shared focus on better patient outcomes,” Ms Shelly said.
“Medicines safety is fundamental to a stronger, safer health system. While we’re pleased to have greater flexibility in how these programs are delivered, there is still more to achieve, and today’s announcement provides a strong foundation for the work to come.
The announcement reflects the success of sustained advocacy by PSA and its members, together with constructive engagement with the Australian Government. PSA remains committed to working collaboratively with Government to progress the 1PPA.
Brooke Shelly FPS is a rural Victorian pharmacist with a dynamic portfolio career spanning General Practice, credentialed medication management and residential medication management reviews, and multidisciplinary telehealth. She is a GP Pharmacist at Ontario Medical Clinic, a Senior Clinical Pharmacist with Beyond Pain, and the sole proprietor of MyMedManagement, delivering complex medication and residential medication management reviews across regional and remote areas.
Source: Adapted from PSA media release, July 2026
-
Understanding factors of persistent lower back pain in women
Lizzy Quinn is a Musculoskeletal Physiotherapist with 20 years experience focusing on people with spinal pain. Australian Health Journal spoke with Lizzy on the complexities of persistent lower back pain in women.
Lower back pain in women in their 30s, 40s, and 50s is complex to treat due to the combination of physical and emotional factors, and health professionals need to stay updated on best practices and science to provide the best recovery platform for patients. These women typically have busy lives, pressures, and expectations.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
-
Strategic research investments for health and prosperity
The CEO of Research Australia, Nadia Levin spoke with Australian Health Journal about the following:
– Current medical research and development landscape in Australia
– Investment required to support the Health and Medical Research and Innovation pipeline
– The National Medical Products Industry Plan and its impact on the Australian economy
– The Health and Medical Research WorkforceIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
